PTPI Research and Charts

PTPI - Petros Pharmaceuticals Inc Ordinary Shares (Healthcare: Drug Manufacturers - Specialty & Generic)

Projected Earnings Date: 2021-08-16 (Delayed quote data 2025-01-06)

Last 0.41	Change ⇑ +0.01 (+0.00%)	Volume 990,591
	Open 0.39	High 0.42	Low 0.37

8EMA (Daily) 0.39	40EMA (Daily) 0.34	50EMA (Daily) 0.34	STO (Daily) 46.471	MACD Hist (Daily) 0.020
8EMA (Weekly) 0.353	40EMA (Weekly) 0.55	50EMA (Weekly) 0.65	STO (Weekly) 40.811	MACD Hist (Weekly) 0.071


Company Profile
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Prescription Medications segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.